Now showing items 51-70 of 84

      Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data [1]
      Neuraminidase inhibitors--the story behind the Cochrane review [1]
      No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility [1]
      Noninferiority Trials [letter to the editor] [1]
      North American regulatory agencies can and should make clinical trial data publicly available [1]
      Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency [1]
      Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments [1]
      Pandemrix vaccine: why was the public not told of early warning signs? [1]
      Patient consent to publication and data sharing in industry and NIH-funded clinical trials [2]
      Popular and scientific attitudes regarding pandemic influenza [1]
      The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us? [1]
      Preventing flu-like illness: Reason for optimism [1]
      The problem with US website for collecting adverse events after vaccination is resolved [1]
      Putting GlaxoSmithKline to the test over paroxetine [1]
      Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling. [1]
      Restoring biomedical literature with RIAT [1]
      Restoring invisible and abandoned trials: a call for people to publish the findings [1]
      Rethinking credible evidence synthesis [1]
      Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports [1]
      Speeding new antibiotics to market: a fake fix? [1]